argenx SE (NASDAQ:ARGX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

argenx SE (NASDAQ:ARGX) has received a consensus rating of “Moderate Buy” from the twenty-one brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, fourteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $528.16.

A number of research analysts recently issued reports on ARGX shares. Wells Fargo & Company lifted their target price on argenx from $472.00 to $478.00 and gave the stock an “overweight” rating in a report on Tuesday, February 20th. Truist Financial lifted their target price on argenx from $370.00 to $440.00 and gave the stock a “buy” rating in a report on Tuesday, March 5th. Robert W. Baird lowered their target price on argenx from $505.00 to $490.00 and set an “outperform” rating on the stock in a report on Friday, March 1st. Scotiabank lifted their target price on argenx from $402.00 to $408.00 and gave the stock a “sector perform” rating in a report on Tuesday, March 26th. Finally, Wolfe Research began coverage on argenx in a research note on Thursday, February 15th. They issued a “peer perform” rating on the stock.

argenx Stock Up 1.7 %

Shares of NASDAQ ARGX opened at $375.08 on Wednesday. argenx has a fifty-two week low of $327.73 and a fifty-two week high of $550.76. The firm’s 50-day simple moving average is $386.95 and its 200 day simple moving average is $419.33. The stock has a market cap of $22.29 billion, a P/E ratio of -72.97 and a beta of 0.65.

argenx (NASDAQ:ARGX) last released its earnings results on Thursday, February 29th. The company reported ($1.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.45). The firm had revenue of $417.84 million for the quarter, compared to analyst estimates of $378.60 million. argenx had a negative return on equity of 16.97% and a negative net margin of 23.26%. During the same period in the previous year, the firm earned ($0.70) earnings per share. On average, sell-side analysts anticipate that argenx will post -2.1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On argenx

Several institutional investors have recently made changes to their positions in ARGX. Parkside Financial Bank & Trust acquired a new stake in shares of argenx during the 3rd quarter valued at about $28,000. GAMMA Investing LLC lifted its holdings in shares of argenx by 420.0% during the 1st quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock valued at $31,000 after buying an additional 63 shares during the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of argenx during the 4th quarter valued at about $38,000. Mather Group LLC. acquired a new stake in shares of argenx during the 1st quarter valued at about $38,000. Finally, Nkcfo LLC lifted its holdings in shares of argenx by 22.1% during the 3rd quarter. Nkcfo LLC now owns 116 shares of the company’s stock valued at $57,000 after buying an additional 21 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.